“Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?”
European Journal of Cancer · 2026-06 · 241 · 116796
DOI: 10.1016/j.ejca.2026.116796 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Fabio Conforti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Humanitas University, Milan, Italy; Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy. Electronic address: fabio.conforti@hunimed.eu. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
The therapeutic landscape for HER2-positive breast cancer (BC) is evolving rapidly with the advent of antibody-drug conjugates such as trastuzumab deruxtecan (T-DXd). Recently, positive results from the Destiny Breast 011 (DB11) randomized clinical trial were reported, seemingly supporting T-DXd followed by paclitaxel, trastuzumab, and pertuzumab as a potential new neoadjuvant treatment option for high-risk, HER2-positive early breast cancer (eBC). However, in our view, several elements of the trial's design and conduct may have affected the results both qualitatively and quantitatively. These concerns include the selection of the primary endpoint, the sample-size calculation, potential source of bias and the suboptimal post-recurrence therapies administered to patients enrolled. Taken together, these limitations substantially constrain the interpretability of the trial's findings. In this commentary, we discuss why, although the DB11 results are encouraging and justify continued exploration of this innovative therapeutic strategy, the current evidence remains insufficient to support upfront neoadjuvant T-DXd as a standard-of-care option for patients with high-risk, HER2-positive eBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Humanitas University, Milan, Italy; Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy. Electronic address: fabio.conforti@hunimed.eu.
- Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
- Humanitas University, Milan, Italy; Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy.
- Humanitas University, Milan, Italy.
- Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy.
- Department of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Harvard T.H. Chan School of Public Health, and, Frontier Science & Technology Research Foundation, Boston, USA.
Zitieren
APA
Conforti, F., Sala, I., Pala, L., Bendoni, M., Canzian, J., Tinterri, B., De Pas, T., Locatelli, M., Bagnardi, V., & Gelber, R. (2026). “Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?”. European Journal of Cancer, 241, 116796. https://doi.org/10.1016/j.ejca.2026.116796
Vancouver
Conforti F, Sala I, Pala L, Bendoni M, Canzian J, Tinterri B, et al. “Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?”. European Journal of Cancer. 2026;241:116796. doi:10.1016/j.ejca.2026.116796
BibTeX
@article{Conforti2026,
author = {Conforti, Fabio and Sala, Isabella and Pala, Laura and Bendoni, Marzia and Canzian, Jacopo and Tinterri, Benedetta and De Pas, Tommaso and Locatelli, Marzia and Bagnardi, Vincenzo and Gelber, Richard},
title = {“Neoadjuvant trastuzumab deruxtecan for high-risk HER2-positive early breast cancer: Does the evidence support its use as a new standard-of-care?”},
journal = {European Journal of Cancer},
year = {2026},
volume = {241},
pages = {116796},
doi = {10.1016/j.ejca.2026.116796}
}
EUVIMED